144 related articles for article (PubMed ID: 18332608)
1. Effects of pitavastatin on adiponectin in patients with hyperlipidemia.
Inami N; Nomura S; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Nanba M; Shouda Y; Iwasaka T
Pathophysiol Haemost Thromb; 2007; 36(1):1-8. PubMed ID: 18332608
[TBL] [Abstract][Full Text] [Related]
2. Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients.
Nomura S; Shouzu A; Omoto S; Inami N; Shimazu T; Satoh D; Kajiura T; Yamada K; Urase F; Maeda Y; Iwasaka T
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):440-7. PubMed ID: 19525846
[TBL] [Abstract][Full Text] [Related]
3. Correlation between adiponectin and reduction of cell adhesion molecules after pitavastatin treatment in hyperlipidemic patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Inami N; Tanaka A; Nanba M; Shouda Y; Takahashi N; Kimura Y; Iwasaka T
Thromb Res; 2008; 122(1):39-45. PubMed ID: 17920663
[TBL] [Abstract][Full Text] [Related]
4. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients.
Nomura S; Inami N; Shouzu A; Omoto S; Kimura Y; Takahashi N; Tanaka A; Urase F; Maeda Y; Ohtani H; Iwasaka T
Platelets; 2009 Feb; 20(1):16-22. PubMed ID: 19172517
[TBL] [Abstract][Full Text] [Related]
5. Impact of pitavastatin on high-sensitivity C-reactive protein and adiponectin in hypercholesterolemic patients with the metabolic syndrome: the PREMIUM Study.
Matsubara T; Naruse K; Arakawa T; Nakao M; Yokoi K; Oguri M; Marui N; Amano T; Ichimiya S; Ohashi T; Imai K; Sakai S; Sugiyama S; Ishii H; Murohara T
J Cardiol; 2012 Nov; 60(5):389-94. PubMed ID: 22884685
[TBL] [Abstract][Full Text] [Related]
6. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
7. Pitavastatin further decreases serum high-sensitive C-reactive protein levels in hypertensive patients with hypercholesterolemia treated with angiotensin II, type-1 receptor antagonists.
Yoshika M; Komiyama Y; Masuda M; Yokoi T; Masaki H; Ohkura H; Takahashi H
Clin Exp Hypertens; 2010; 32(6):341-6. PubMed ID: 21028996
[TBL] [Abstract][Full Text] [Related]
8. Effect of low-dose (1 mg/day) pitavastatin on left ventricular diastolic function and albuminuria in patients with hyperlipidemia.
Yagi S; Akaike M; Aihara K; Iwase T; Ishikawa K; Yoshida S; Sumitomo-Ueda Y; Kusunose K; Niki T; Yamaguchi K; Koshiba K; Taketani Y; Tomita N; Yamada H; Soeki T; Wakatsuki T; Matsumoto T; Sata M
Am J Cardiol; 2011 Jun; 107(11):1644-9. PubMed ID: 21458773
[TBL] [Abstract][Full Text] [Related]
9. Effect of atorvastatin on type 2 diabetic dyslipidemia.
Save V; Patil N; Moulik N; Rajadhyaksha G
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):262-70. PubMed ID: 17220473
[TBL] [Abstract][Full Text] [Related]
10. Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Yee LL; Wright EA
Clin Ther; 2011 Aug; 33(8):1023-42. PubMed ID: 21816477
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
[TBL] [Abstract][Full Text] [Related]
12. No effect of lipid lowering on platelet activity in patients with coronary artery disease and type 2 diabetes or impaired glucose tolerance.
Malmström RE; Settergren M; Böhm F; Pernow J; Hjemdahl P
Thromb Haemost; 2009 Jan; 101(1):157-64. PubMed ID: 19132203
[TBL] [Abstract][Full Text] [Related]
13. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Shouzu A; Omoto S; Nishikawa M; Fukuhara S; Iwasaka T
Thromb Res; 2006; 117(4):385-92. PubMed ID: 15896827
[TBL] [Abstract][Full Text] [Related]
14. Pitavastatin and carbohydrate metabolism: what is the evidence?
Filippatos TD; Elisaf MS
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):955-60. PubMed ID: 26967972
[TBL] [Abstract][Full Text] [Related]
15. Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus.
Nomura S; Inami N; Kimura Y; Omoto S; Shouzu A; Nishikawa M; Iwasaka T
J Hum Hypertens; 2007 Jan; 21(1):38-44. PubMed ID: 17051237
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients.
Celik T; Iyisoy A; Kursaklioglu H; Kardesoglu E; Kilic S; Turhan H; Yilmaz MI; Ozcan O; Yaman H; Isik E; Fici F
J Hypertens; 2006 Mar; 24(3):591-6. PubMed ID: 16467663
[TBL] [Abstract][Full Text] [Related]
17. Pitavastatin prevents intestinal ischemia/reperfusion-induced bacterial translocation and lung injury in atherosclerotic rats with hypoadiponectinemia.
Nakagawa H; Tsunooka N; Yamamoto Y; Yoshida M; Nakata T; Kawachi K
Surgery; 2009 May; 145(5):542-9. PubMed ID: 19375614
[TBL] [Abstract][Full Text] [Related]
18. High plasma C-reactive protein (CRP) is related to low paraoxonase-I (PON-I) activity independently of high leptin and low adiponectin in type 2 diabetes mellitus.
Dullaart RP; de Vries R; Sluiter WJ; Voorbij HA
Clin Endocrinol (Oxf); 2009 Feb; 70(2):221-6. PubMed ID: 18505467
[TBL] [Abstract][Full Text] [Related]
19. High sensitive C-reactive protein, adiponectin, and urine albumin excretion rate in Chinese coronary artery disease patients with different glucose tolerance status.
Gui MH; Hong J; Lü AK; Chen Y; Shen WF; Li XY; Ning G
Chin Med J (Engl); 2008 Dec; 121(24):2509-16. PubMed ID: 19187587
[TBL] [Abstract][Full Text] [Related]
20. Low serum adiponectin is associated with high circulating oxidized low-density lipoprotein in patients with type 2 diabetes mellitus and coronary artery disease.
Lautamäki R; Rönnemaa T; Huupponen R; Lehtimäki T; Iozzo P; Airaksinen KE; Knuuti J; Nuutila P
Metabolism; 2007 Jul; 56(7):881-6. PubMed ID: 17570246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
